Market Research Logo

Brain Cancer - Pipeline Review, H1 2015

Brain Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Brain Cancer - Pipeline Review, H1 2015’, provides an overview of the Brain Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Brain Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Brain Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Brain Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Brain Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Brain Cancer Overview
Therapeutics Development
Pipeline Products for Brain Cancer – Overview
Pipeline Products for Brain Cancer – Comparative Analysis
Brain Cancer – Therapeutics under Development by Companies
Brain Cancer – Therapeutics under Investigation by Universities/Institutes
Brain Cancer – Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Brain Cancer – Products under Development by Companies
Brain Cancer – Products under Investigation by Universities/Institutes
Brain Cancer – Companies Involved in Therapeutics Development
AbbVie Inc.
AngioChem Inc.
Arrien Pharmaceuticals, LLC
BBB Therapeutics B.V.
biOasis Technologies Inc.
Bionomics Limited
Bristol-Myers Squibb Company
Cavion LLC
Critical Outcome Technologies Inc.
CureFAKtor Pharmaceuticals, LLC
Diffusion Pharmaceuticals LLC
e-Therapeutics plc
Eisai Co., Ltd.
Exelixis, Inc.
GlaxoSmithKline plc
Hutchison MediPharma Limited
Merrimack Pharmaceuticals, Inc.
Nanobiotix
Nektar Therapeutics
Nerviano Medical Sciences S.r.l.
Neuralstem, Inc.
Novartis AG
Oncology Research International Limited
Pfizer Inc.
Philogen S.p.A.
Phosplatin Therapeutics
Prana Biotechnology Limited
Puma Biotechnology, Inc.
RadioRx, Inc.
Sagetis Biotech, S.L.
Sanofi
Spectrum Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Takeda Pharmaceutical Company Limited
ThromboGenics NV
Tocagen Inc.
Zymeworks Inc.
Brain Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile
2B3-101 - Drug Profile
ANG-1005 - Drug Profile
ANG-4043 - Drug Profile
ARN-7016 - Drug Profile
BNC-105 - Drug Profile
BT-2111 - Drug Profile
cabazitaxel - Drug Profile
cabozantinib s-malate - Drug Profile
CFAKC-4 - Drug Profile
COTI-2 - Drug Profile
dabrafenib mesylate - Drug Profile
dacomitinib - Drug Profile
dexanabinol - Drug Profile
Drug for Brain Metastasis - Drug Profile
erismodegib - Drug Profile
etirinotecan pegol - Drug Profile
Gene Therapy for Brain Cancer - Drug Profile
Gene Therapy to Activate p53 for Oncology - Drug Profile
HMPL-813 - Drug Profile
ipilimumab - Drug Profile
irinotecan sucrosofate liposomal - Drug Profile
KML-001 - Drug Profile
lapatinib ditosylate - Drug Profile
LEQ-506 - Drug Profile
lucanthone hydrochloride - Drug Profile
MDNA-55 - Drug Profile
mibefradil dihydrochloride - Drug Profile
Monoclonal Antibody for Brain Cancer and Metastatic Breast Cancer - Drug Profile
NBTX-IV - Drug Profile
neratinib - Drug Profile
nimotuzumab - Drug Profile
NMSE-973 - Drug Profile
NSI-566 - Drug Profile
ORIL-007 - Drug Profile
PB-357 - Drug Profile
PBT-519 - Drug Profile
pritumumab - Drug Profile
PT-112 - Drug Profile
RAD-1901 - Drug Profile
radretumab - Drug Profile
RRX-001 - Drug Profile
SAG-002 - Drug Profile
SAG-003 - Drug Profile
siomycin A - Drug Profile
SL-301 - Drug Profile
SL-302 - Drug Profile
Small Molecule for Brain Cancer - Drug Profile
Small Molecule for Brain Cancer and Malignant Glioma - Drug Profile
Small Molecule for Oncology - Drug Profile
Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma - Drug Profile
TB-403 - Drug Profile
TBX-02 - Drug Profile
TPI-287 - Drug Profile
transcrocetinate sodium - Drug Profile
TTL-1177 - Drug Profile
ubidecarenone - Drug Profile
Vaccine for Glioblastoma Multiforme - Drug Profile
veliparib - Drug Profile
vocimagene amiretrorepvec + flucytosine ER - Drug Profile
Brain Cancer – Recent Pipeline Updates
Brain Cancer – Dormant Projects
Brain Cancer – Discontinued Products
Brain Cancer – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Brain Cancer, H1 2015
Number of Products under Development for Brain Cancer – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2015
Brain Cancer – Pipeline by AbbVie Inc., H1 2015
Brain Cancer – Pipeline by AngioChem Inc., H1 2015
Brain Cancer – Pipeline by Arrien Pharmaceuticals, LLC, H1 2015
Brain Cancer – Pipeline by BBB Therapeutics B.V., H1 2015
Brain Cancer – Pipeline by biOasis Technologies Inc., H1 2015
Brain Cancer – Pipeline by Bionomics Limited, H1 2015
Brain Cancer – Pipeline by Bristol-Myers Squibb Company, H1 2015
Brain Cancer – Pipeline by Cavion LLC, H1 2015
Brain Cancer – Pipeline by Critical Outcome Technologies Inc., H1 2015
Brain Cancer – Pipeline by CureFAKtor Pharmaceuticals, LLC, H1 2015
Brain Cancer – Pipeline by Diffusion Pharmaceuticals LLC, H1 2015
Brain Cancer – Pipeline by e-Therapeutics plc, H1 2015
Brain Cancer – Pipeline by Eisai Co., Ltd., H1 2015
Brain Cancer – Pipeline by Exelixis, Inc., H1 2015
Brain Cancer – Pipeline by GlaxoSmithKline plc, H1 2015
Brain Cancer – Pipeline by Hutchison MediPharma Limited, H1 2015
Brain Cancer – Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015
Brain Cancer – Pipeline by Nanobiotix, H1 2015
Brain Cancer – Pipeline by Nektar Therapeutics, H1 2015
Brain Cancer – Pipeline by Nerviano Medical Sciences S.r.l., H1 2015
Brain Cancer – Pipeline by Neuralstem, Inc., H1 2015
Brain Cancer – Pipeline by Novartis AG, H1 2015
Brain Cancer – Pipeline by Oncology Research International Limited, H1 2015
Brain Cancer – Pipeline by Pfizer Inc., H1 2015
Brain Cancer – Pipeline by Philogen S.p.A., H1 2015
Brain Cancer – Pipeline by Phosplatin Therapeutics, H1 2015
Brain Cancer – Pipeline by Prana Biotechnology Limited, H1 2015
Brain Cancer – Pipeline by Puma Biotechnology, Inc., H1 2015
Brain Cancer – Pipeline by RadioRx, Inc., H1 2015
Brain Cancer – Pipeline by Sagetis Biotech, S.L., H1 2015
Brain Cancer – Pipeline by Sanofi, H1 2015
Brain Cancer – Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015
Brain Cancer – Pipeline by Stemline Therapeutics, Inc., H1 2015
Brain Cancer – Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
Brain Cancer – Pipeline by ThromboGenics NV, H1 2015
Brain Cancer – Pipeline by Tocagen Inc., H1 2015
Brain Cancer – Pipeline by Zymeworks Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Brain Cancer Therapeutics – Recent Pipeline Updates, H1 2015
Brain Cancer – Dormant Projects, H1 2015
Brain Cancer – Dormant Projects (Contd..1), H1 2015
Brain Cancer – Dormant Projects (Contd..2), H1 2015
Brain Cancer – Dormant Projects (Contd..3), H1 2015
Brain Cancer – Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Brain Cancer, H1 2015
Number of Products under Development for Brain Cancer – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report